Evaluation of Rofenaid and a commercial bacterin for prevention of cranial form of fowl cholera in turkeys.
Rofenaid, a potentiated sulfadimethoxine at drug concentrations of 0.04, 0.02, and 0.01% in feed, a combination of vaccination with a commercial bacterin and 0.01% potentiated sulfadimethoxine (Rofenaid), and vaccination separately, significantly (P less than 0.05) increased livability of turkeys experimentally induced with the cranial form of fowl cholera as compared to that of the nonmedicated nonvaccinated exposed turkeys. Turkeys were exposed by the administration of Pasteurella multocida (isolate 8579) in the drinking water.
D000284:Administration, Oral; D000821:Animal Feed; D000818:Animals; D001428:Bacterial Vaccines; D005260:Female; D006257:Head; D010325:Pasteurella / Q000276:immunology*; D010326:Pasteurella Infections / Q000517:prevention & control / Q000662:veterinary*; D011201:Poultry Diseases / Q000517:prevention & control*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D013412:Sulfadimethoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D014422:Turkeys
D001428:Bacterial Vaccines; D011743:Pyrimidines; D013412:Sulfadimethoxine